Blackstone Life Sciences and Boston Scientific have agreed to a $455 million deal to jointly fund development of a minimally invasive heart pump. According to Sina Finance, the companies are developing Vitalyst, a device designed by Boston Scientific to support the heart’s pumping without open-heart surgery. Vitalyst is being developed to treat cardiogenic shock, a medical emergency caused by the heart’s inability to pump enough blood. The deal marks the companies’ first collaboration to fund a Boston Scientific product.